A Phase 1 interventional study of Frespaciguat and Placebo in Pulmonary Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed at 9 sites in 3 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-28.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 397 studies in Hypertension, Pulmonary with a site in United States — 73 open to participants now, 87 under way, 9 of them phase 3. Hypertension, Pulmonary · United States.
Among the 397 studies in Hypertension, Pulmonary with a site in United States, this one is the 167th largest by enrollment of the 286 interventional ones that give a count, is one of 10 that started in 2020, is one of 28 in phase 1, and was the 297th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.
Browse Hypertension, Pulmonary studies →73 of the 397 studies in Hypertension, Pulmonary with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–80
University of California, Davis · Sites in United States
Ages up to 28 days
Tectonic Operating Company, Inc. · Sites in United States, Poland, Romania and 3 more countries
Ages 18–80
35Pharma Inc., a GSK company · Sites in United States
Ages 18+
National Institutes of Health Clinical Center (CC) · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
397 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 114 · Phase 3 75 · Phase 4 38
First in 1992; this study’s year is marked. 10 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 30 across the 286 interventional studies, 108 across the 107 observational. Of the 273 that completed or were terminated, 139 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
158 of 397 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 9 studies filed under Hypertension, Pulmonary — fewer than ten, so there is no comparison to draw.
21 of the studies in Hypertension, Pulmonary with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06616974Tectonic TherapeuticA Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) | 2026-11-24 |
| NCT07333183Pulmovant, Inc.A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD | 2026-12 |
| NCT05442671Children's Hospital of PhiladelphiaiTONE Trial (exercIse Training in pulmONary hypertEnsion) Exercise Program for Pediatric PH | 2026-12-31 |
| NCT04808596University of Kansas Medical CenterPulmonary Hypertension Biorepository and Registry | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 397 studies in Hypertension, Pulmonary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are to assess the safety/tolerability and efficacy (by evaluating changes in pulmonary vascular resistance [PVR] and pulmonary blood volume [PBV]) of frespaciguat in participants with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The primary hypothesis is that 28 days of frespaciguat treatment is superior to placebo treatment in reduction of PVR.
Part 1 of this study will assess safety, tolerability, and PK of frespaciguat compared to placebo. Part 2 will assess safety, tolerability, PK, and changes in PVR and PBV of frespaciguat compared to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive frespaciguat 360 μg once daily (QD) via inhalation from Days 1-7. Following review of pharmacokinetic (PK) and safety data, a second 7 days of dosing may be initiated. A dose of up to 360 μg up to twice a day may be administered based on PK data in these participants.
Drug: Frespaciguat
Participants receive placebo QD via inhalation from Days 1-7.
Drug: Placebo
Participants receive frespaciguat 32 µg, 100 µg, 195 µg or 380 μg QD via inhalation from Days 1-28.
Drug: Frespaciguat
Participants receive placebo QD via inhalation from Days 1-28.
Drug: Placebo
Frespaciguat 32 µg, 100 µg, 195 µg, 360 µg or 380 µg administered as dry powder inhalation according to randomization. Following review of pharmacokinetic (PK) and safety data, a second 7 days of dosing may be initiated. A dose of up to 360 μg up to twice a day may be administered based on PK data. Dosage may be adjusted downwards in Part 2, if indicated by PK results in Part 1.
Also known as: MK-5475
Placebo administered as dry powder inhalation according to randomization
Percentage of Participants Who Experienced at Least 1 Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE was assessed.
Time frame: Up to approximately 139 days
Percentage of Participants Who Discontinued Study Drug Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued treatment due to an AE was assessed.
Time frame: Up to approximately 32 days
Percentage Change From Baseline to Day 28 in Pulmonary Vascular Resistance (PVR): Part 2
PVR was calculated in participants after MK-5475 dosing at baseline and Day 28. Based on the variables obtained by right heart catheterization (RHC), the fold change from baseline individual PVR was calculated. The difference from baseline was assessed on the log scale and then back-transformed for reporting (percent change from baseline). Per protocol, this outcome measure was only assessed during the Part 2 and was not assessed during part 1.
Time frame: Baseline (between Day -5 and Day -1) and Day 28
Plasma Area Under the Concentration Time-Curve From 0 to Infinity (AUC0-inf) of MK-5475: Part 1
Blood samples were taken predose and at specified times postdose to determine the AUC0-inf of MK-5475. Plasma AUC0-inf was defined as the area under the concentration vs. time curve for MK-5475 from 0 to infinite hours.
Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
Plasma Area Under the Concentration Time-Curve From 0 to 24 Hours (AUC0-24) of MK-5475: Part 1
Blood samples were taken predose and at specified times postdose on Day 7 to determine the AUC0-24 of MK-5475. AUC0-24 values for Day 1 correspond to extrapolated values since collection on Day 1 stopped at 8 hours.
Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
Maximum Observed Plasma Concentration (Cmax) of MK-5475: Part 1
Plasma concentration of MK-5475 was quantified for each arm to determine Cmax.
Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
Plasma Concentration 24 Hours Postdose (C24) of MK-5475: Part 1
Blood samples were taken to determine the C24 of MK-5475. Data are reported as Mean with Standard Deviation. Concentration values below the lower limit of quantification were treated as having a value of 0.
Time frame: 24 hours postdose on Day 7
Time to Maximum Concentration (Tmax) of MK-5475: Part 1
Blood samples were taken at predose and at specified time points postdose to determine the Tmax of MK-5475. Tmax was defined as the time to maximum concentration of MK-5475.
Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
Plasma Apparent Terminal Half-Life (t½) of MK-5475: Part 1
Blood samples were taken at predose and at specified time points postdose to determine the t½ of MK-5475.
Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
Cmax Accumulation Ratio of MK-5475: Part 1
Blood samples were taken predose and at specified times postdose to determine the Cmax accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 Cmax to the Day 1 Cmax.
Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
AUC0-24 Accumulation Ratio of MK-5475: Part 1
Blood samples were taken predose and at specified times postdose to determine the AUC0-24 accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 AUC0-24 to the Day 1 AUC0-24.
Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
AUC0-inf Accumulation Ratio of MK-5475: Part 1
Blood samples were taken predose and at specified times postdose on Days 1-7 to determine the AUC0-inf accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 AUC0-inf to the Day 1 AUC0-inf.
Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
AUC0-inf of MK-5475: Part 2
Blood samples were taken pre-dose and at specified times post-dose to determine the AUC0-inf of MK-5475. Concentrations for samples collected pre-RHC in a time window of 6-8 hours postdose on Day 28 were used to derive PK parameter values on Day 28. A nominal elapsed time of 6.01 hours postdose was used in the calculation.
Time frame: Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose
AUC0-24 of MK-5475: Part 2
Blood samples were taken predose and at specified times postdose on Day 28 to determine the AUC0-24 of MK-5475. Concentrations for samples collected pre-RHC in a time window of 6-8 hours postdose on Day 28 were used to derive PK parameter values on Day 28. A nominal elapsed time of 6.01 hours postdose was used in the calculation. AUC0-24 was calculated using extrapolated concentration at 24 hours postdose.
Time frame: Day 28: Predose, 0.5, 1, 2 and 3 hours postdose
Cmax of MK-5475: Part 2
Blood samples were taken predose and at specified times postdose to determine the Cmax of MK-5475.
Time frame: Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose
Plasma Concentration 24 Hours Postdose (C24) of MK-5475: Part 2
Blood samples were taken to determine the C24 of MK-5475. Data are reported as Mean with Coefficient of Variation, but due to data entry limitations the table below labels them as Geometric Mean and Geometric Coefficient of Variation. Concentration values below the lower limit of quantification were treated as having a value of 0.
Time frame: 24 hours postdose on Day 7
Tmax of MK-5475: Part 2
Blood samples were taken predose and at specified times postdose to determine the Tmax of MK-5475.
Time frame: Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose
t½ of MK-5475: Part 2
Blood samples were taken predose and at specified times postdose to determine the t½ of MK-5475.
Time frame: Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose
AUC0-3 Accumulation Ratio of MK-5475: Part 2
Blood samples were taken predose and at specified times postdose on to determine the AUC0-3 accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 AUC0-3 to the Day 1 AUC0-3.
Time frame: Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose
Cmax Accumulation Ratio of MK-5475: Part 2
Blood samples were taken predose and at specified times postdose to determine the Cmax accumulation ratio of MK-5475. Cmax accumulation ratio is the ratio of the Day 7 Cmax to the Day 1 Cmax.
Time frame: Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 15: 1 hour postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose
Percent Change From Baseline in Pulmonary Blood Volume (PBV) at Day 28: Part 2
Participants underwent a series of computed tomography (CT) scans with an intravenous (IV) iodinated contrast agent to facilitate assessment of PBV at baseline and at several times points after MK-5475 dosing. Percentage change from baseline (CFB) in PBV was calculated and reported for each dose group that underwent FRI in Part 2. As pre-specified, central tendency for PBV percentage CFB was provided as numerical values rounded to whole numbers. Per protocol, this outcome measure was only assessed during the Part 2 FRI Period for each panel and was not assessed during part 1 and part 3.
Time frame: Baseline (between Day -5 and Day -1) and Day 28
Adult participants with pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (COPD) were recruited to evaluate safety, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of MK-5475.
| Milestone | Part 1: MK-5475 360 μg | Part 1: Placebo | Part 2: MK-5475 380 μg | Part 2: Placebo |
|---|---|---|---|---|
| Started | 6 | 3 | 0 | 0 |
| Completed | 6 | 3 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Part 1: MK-5475 360 μg | Part 1: Placebo | Part 2: MK-5475 380 μg | Part 2: Placebo |
|---|---|---|---|---|
| Started | 0 | 0 | 8 | 5 |
| Completed | 0 | 0 | 8 | 5 |
| Not completed | 0 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE was assessed.
| Percentage of Participants | Part 1: MK-5475 360 μg | Part 1: Placebo | Part 2: MK-5475 380 μg | Part 2: Placebo |
|---|---|---|---|---|
| Percentage of Participants Who Experienced at Least 1 Adverse Event (AE) | 33.3 | 33.3 | 33.3 | 80.0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued treatment due to an AE was assessed.
| Percentage of Participants | Part 1: MK-5475 360 μg | Part 1: Placebo | Part 2: MK-5475 380 μg | Part 2: Placebo |
|---|---|---|---|---|
| Percentage of Participants Who Discontinued Study Drug Due to an AE | 0.0 | 0.0 | 0.0 | 0.0 |
PVR was calculated in participants after MK-5475 dosing at baseline and Day 28. Based on the variables obtained by right heart catheterization (RHC), the fold change from baseline individual PVR was calculated. The difference from baseline was assessed on the log scale and then back-transformed for reporting (percent change from baseline). Per protocol, this outcome measure was only assessed during the Part 2 and was not assessed during part 1.
| Percentage change | Part 2: MK-5475 380 μg | Part 2: Placebo |
|---|---|---|
| Percentage Change From Baseline to Day 28 in Pulmonary Vascular Resistance (PVR): Part 2 | -21.23 ± 16.98 | -5.39 ± 49.21 |
Blood samples were taken predose and at specified times postdose to determine the AUC0-inf of MK-5475. Plasma AUC0-inf was defined as the area under the concentration vs. time curve for MK-5475 from 0 to infinite hours.
| hr*nM | Part 1: MK-5475 360 μg |
|---|---|
| Day 1 | 3.32 ± 68.9 |
| Day 7 | 4.03 ± 90.2 |
Blood samples were taken predose and at specified times postdose on Day 7 to determine the AUC0-24 of MK-5475. AUC0-24 values for Day 1 correspond to extrapolated values since collection on Day 1 stopped at 8 hours.
| hr*nM | Part 1: MK-5475 360 μg |
|---|---|
| Day 1 | 3.31 ± 68.7 |
| Day 7 | 4.22 ± 83.5 |
Plasma concentration of MK-5475 was quantified for each arm to determine Cmax.
| nM | Part 1: MK-5475 360 μg |
|---|---|
| Day 1 | 0.830 ± 50.8 |
| Day 7 | 0.970 ± 59.1 |
Blood samples were taken to determine the C24 of MK-5475. Data are reported as Mean with Standard Deviation. Concentration values below the lower limit of quantification were treated as having a value of 0.
| nM | Part 1: MK-5475 360 μg |
|---|---|
| Plasma Concentration 24 Hours Postdose (C24) of MK-5475: Part 1 | 0.02 ± 0.3 |
Blood samples were taken at predose and at specified time points postdose to determine the Tmax of MK-5475. Tmax was defined as the time to maximum concentration of MK-5475.
| Hours | Part 1: MK-5475 360 μg |
|---|---|
| Day 1 | 1.00 (1.00 to 2.00) |
| Day 7 | 1.00 (1.00 to 2.00) |
Blood samples were taken at predose and at specified time points postdose to determine the t½ of MK-5475.
| Hours | Part 1: MK-5475 360 μg |
|---|---|
| Day 1 | 2.13 ± 18.5 |
| Day 7 | 2.81 ± 48.4 |
Blood samples were taken predose and at specified times postdose to determine the Cmax accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 Cmax to the Day 1 Cmax.
| Ratio | Part 1: MK-5475 360 μg |
|---|---|
| Cmax Accumulation Ratio of MK-5475: Part 1 | 1.17 ± 28.8 |
Blood samples were taken predose and at specified times postdose to determine the AUC0-24 accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 AUC0-24 to the Day 1 AUC0-24.
| Ratio | Part 1: MK-5475 360 μg |
|---|---|
| AUC0-24 Accumulation Ratio of MK-5475: Part 1 | 1.27 ± 30.1 |
Blood samples were taken predose and at specified times postdose on Days 1-7 to determine the AUC0-inf accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 AUC0-inf to the Day 1 AUC0-inf.
| Ratio | Part 1: MK-5475 360 μg |
|---|---|
| AUC0-inf Accumulation Ratio of MK-5475: Part 1 | 1.21 ± 31.1 |
Blood samples were taken pre-dose and at specified times post-dose to determine the AUC0-inf of MK-5475. Concentrations for samples collected pre-RHC in a time window of 6-8 hours postdose on Day 28 were used to derive PK parameter values on Day 28. A nominal elapsed time of 6.01 hours postdose was used in the calculation.
| hr*nM | Part 2: MK-5475 380 μg |
|---|---|
| Day 1 | NA ± NA |
| Day 28 | 1.98 ± 105.9 |
Blood samples were taken predose and at specified times postdose on Day 28 to determine the AUC0-24 of MK-5475. Concentrations for samples collected pre-RHC in a time window of 6-8 hours postdose on Day 28 were used to derive PK parameter values on Day 28. A nominal elapsed time of 6.01 hours postdose was used in the calculation. AUC0-24 was calculated using extrapolated concentration at 24 hours postdose.
| hr*nM | Part 2: MK-5475 380 μg |
|---|---|
| Day 1 | NA ± NA |
| Day 28 | 1.97 ± 105.7 |
Blood samples were taken predose and at specified times postdose to determine the Cmax of MK-5475.
| nM | Part 2: MK-5475 380 μg |
|---|---|
| Day 1 | 0.348 ± 48.4 |
| Day 28 | 0.397 ± 71.4 |
Blood samples were taken to determine the C24 of MK-5475. Data are reported as Mean with Coefficient of Variation, but due to data entry limitations the table below labels them as Geometric Mean and Geometric Coefficient of Variation. Concentration values below the lower limit of quantification were treated as having a value of 0.
No measurements were reported for this outcome.
Blood samples were taken predose and at specified times postdose to determine the Tmax of MK-5475.
| Hours | Part 2: MK-5475 380 μg |
|---|---|
| Day 1 | 1.50 (1.00 to 2.00) |
| Day 28 | 1.50 (1.00 to 2.00) |
Blood samples were taken predose and at specified times postdose to determine the t½ of MK-5475.
| Hours | Part 2: MK-5475 380 μg |
|---|---|
| Day 1 | NA ± NA |
| Day 28 | 2.06 ± 62.4 |
Blood samples were taken predose and at specified times postdose on to determine the AUC0-3 accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 AUC0-3 to the Day 1 AUC0-3.
| Ratio | Part 2: MK-5475 380 μg |
|---|---|
| AUC0-3 Accumulation Ratio of MK-5475: Part 2 | 1.11 ± 53.8 |
Blood samples were taken predose and at specified times postdose to determine the Cmax accumulation ratio of MK-5475. Cmax accumulation ratio is the ratio of the Day 7 Cmax to the Day 1 Cmax.
| Ratio | Part 2: MK-5475 380 μg |
|---|---|
| Cmax Accumulation Ratio of MK-5475: Part 2 | 1.14 ± 51.6 |
Participants underwent a series of computed tomography (CT) scans with an intravenous (IV) iodinated contrast agent to facilitate assessment of PBV at baseline and at several times points after MK-5475 dosing. Percentage change from baseline (CFB) in PBV was calculated and reported for each dose group that underwent FRI in Part 2. As pre-specified, central tendency for PBV percentage CFB was provided as numerical values rounded to whole numbers. Per protocol, this outcome measure was only assessed during the Part 2 FRI Period for each panel and was not assessed during part 1 and part 3.
| Percentage Change | Part 2: MK-5475 380 μg | Part 2: Placebo |
|---|---|---|
| Percent Change From Baseline in Pulmonary Blood Volume (PBV) at Day 28: Part 2 | -0.3 ± 4.7 | -2.8 ± 10.6 |
Collected over Up to approximately 139 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MK-5475 360 µg (Part 1) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Placebo (Part 1) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| MK-5475 380 µg (Part 2) | 0/9 (0%) | 1/9 (11.1%) | 2/9 (22.2%) |
| Placebo (Part 2) | 0/5 (0%) | 1/5 (20%) | 4/5 (80%) |
| Event | MK-5475 360 µg (Part 1) | Placebo (Part 1) | MK-5475 380 µg (Part 2) | Placebo (Part 2) |
|---|---|---|---|---|
| Cardiac failureCardiac disorders | 0/6 | 0/3 | 0/9 | 1/5 |
| COVID-19Infections and infestations | 0/6 | 0/3 | 1/9 | 0/5 |
| COVID-19 pneumoniaInfections and infestations | 0/6 | 0/3 | 1/9 | 0/5 |
| EncephalopathyNervous system disorders | 0/6 | 0/3 | 1/9 | 0/5 |
| Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders | 0/6 | 0/3 | 1/9 | 0/5 |
| Event | MK-5475 360 µg (Part 1) | Placebo (Part 1) | MK-5475 380 µg (Part 2) | Placebo (Part 2) |
|---|---|---|---|---|
| HeadacheNervous system disorders | 2/6 | 1/3 | 0/9 | 0/5 |
| Lacrimation increasedEye disorders | 0/6 | 0/3 | 0/9 | 1/5 |
| Urinary tract infectionInfections and infestations | 0/6 | 0/3 | 0/9 | 1/5 |
| Accidental overdoseInjury, poisoning and procedural complications | 0/6 | 0/3 | 0/9 | 1/5 |
| Blood creatinine increasedInvestigations | 0/6 | 0/3 | 0/9 | 1/5 |
| DizzinessNervous system disorders | 0/6 | 0/3 | 0/9 | 1/5 |
| AgitationPsychiatric disorders | 0/6 | 0/3 | 1/9 | 1/5 |
| Infusion site extravasationGeneral disorders | 0/6 | 0/3 | 1/9 | 0/5 |
One participant in Part 1 also participated in Part 2. That participant is counted only in Part 1 for baseline characteristics.
| Age, Continuous(Years) | Part 1: MK-5475 360 μg | Part 1: Placebo | Part 2: MK-5475 380 μg | Part 2: Placebo | Total |
|---|---|---|---|---|---|
| Mean | 62.2 ± 12.7 | 62.3 ± 8.7 | 69.4 ± 4.8 | 66.6 ± 5.6 | 65.8 ± 8.4 |
| Sex: Female, Male(Participants) | Part 1: MK-5475 360 μg | Part 1: Placebo | Part 2: MK-5475 380 μg | Part 2: Placebo | Total |
|---|---|---|---|---|---|
| Female | 1 | 2 | 0 | 0 | 3 |
| Male | 5 | 1 | 8 | 5 | 19 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: MK-5475 360 μg | Part 1: Placebo | Part 2: MK-5475 380 μg | Part 2: Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 6 | 3 | 8 | 5 | 22 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1: MK-5475 360 μg | Part 1: Placebo | Part 2: MK-5475 380 μg | Part 2: Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 6 | 3 | 8 | 5 | 22 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Pulmonary Vascular Resistance (PVR): Part 2(dynes*s*cm^-5) | Part 1: MK-5475 360 μg | Part 1: Placebo | Part 2: MK-5475 380 μg | Part 2: Placebo | Total |
|---|---|---|---|---|---|
| Mean | — | — | 409.52 ± 166.47 | 394.32 ± 141.18 | 404.46 ± 152.08 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Jun 2020 to primary completion in Jan 2022, 19 months.
Results were first posted in Apr 2024, 2 years 3 months after primary completion.
Of 21 phase 1 interventional studies under Hypertension, Pulmonary, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 19 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Frespaciguat